MedTrace Logo

Single Ascending Dose (BMS-813160) Study

NCT01049165 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2011-02-11

No results posted yet for this study

Summary

The primary purpose of this study is to evaluate the safety and tolerability of single oral doses of BMS-813160 in healthy subjects

Conditions

  • Accelerated Intimal Hyperplasia

Interventions

DRUG

BMS-813160

Oral Solution, Oral, 5 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 20 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 60 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 150 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 300 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 600 mg, Single Dose, 1 day

DRUG

[14C] BMS-813160

Oral Solution, Oral, 150 mg, Single Dose, 1 day

DRUG

Placebo

Oral Solution, Oral, 0 mg, Single Dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 1200 mg, Single dose, 1 day

DRUG

BMS-813160

Oral Solution, Oral, 2000 mg, Single Dose, 1 day

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01049165 on ClinicalTrials.gov